tonabersat
AssetAlso BL1243, SB-220453
Inhibits gap junctions and hemichannels (specifically connexin 43) to reduce inflammatory signalling.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Inflammation
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Dry age-related macular degeneration
Phase 2, businesswire.com, 6 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Evidence for its targets2
- Competitors3
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.